Skip to content
Search

Latest Stories

Acetazolamide SR capsules face supply disruption

Acetazolamide SR 250mg capsules will remain out of pharmacy shelves until May 2021, the Department of Health and Social Care (DH) has said in its latest medicine supply notification on Monday (Feb 8).

However, Acetazolamide immediate release 250mg tablets will remain available and can support a steep rise in demand. Target Healthcare has confirmed the availability of unlicensed acetazolamide SR 250mg capsules.


“Where prescribing of an unlicensed import is considered appropriate by the prescriber, a prescription must be issued with the wording ‘Special Order’ next to the prescribed product to ensure that a pharmacy can dispense and be correctly reimbursed for a special,” the Pharmacy Services Negotiating Committee (PSNC) said.

There are dm+d ‘Special Order’ listings for several different strengths of the oral suspension including the 250mg/5ml strength which is listed in Part VIIIB of the Drug Tariff.

“However, currently, there is no dm+d listing for the unlicensed Acetazolamide 250mg SR capsules for prescribers to select using their prescribing systems. If  a prescriber wishes to prescribe the imported capsules, a paper prescription should be issued for ‘Acetazolamide 250mg SR capsules (Special Order)‘ and endorsed by the pharmacy as a non-Part VIIIB special,” the PSNC added.

The DH has issued yet another medicine supply notification for Fluoxetine 40mg capsules.

The drug will remain out of stock until the end of March 2021. However, Fluoxetine 20mg capsules remain available and can support any increase in demand.

Advanz is the sole supplier of the antidepressant.

Levothyroxine 12.5microgram tablets will also remain out of stock until early March 2021.

Levothyroxine 25microgram tablets remain available and can support a steep rise in demand.

UKMi have advised that levothyroxine tablets have a long half-life and clinicians should consider prescribing one levothyroxine 25microgram tablet on alternate days until levothyroxine 12.5microgram tablets become available.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less